PharmaVentures announced today the publication of the report 'Competition Law and Intellectual Property Strategy in the Pharmaceuticals Sector', written by Richard Eccles and Gerry Kamstra, partners in the leading international law firm, Bird & Bird, in London.
Oxford, UK (PRWEB) April 17, 2008 -- PharmaVentures announced today the publication of the report 'Competition Law and Intellectual Property Strategy in the Pharmaceuticals Sector', written by Richard Eccles and Gerry Kamstra, partners in the leading international law firm, Bird & Bird, in London.
Fintan Walton, PhD, PharmaVentures' Chief Executive Officer, says, "In our work facilitating strategic transactions within the pharmaceutical and biotech industry worldwide, awareness of the latest competition legislation is crucial as it affects technology licensing, marketing and distribution agreements. In publishing this Report, we are delighted to have collaborated with Bird & Bird who have contributed their leading-edge expertise."
Lead Author of the Report, Richard Eccles says, "We give advice to our clients every day on IP, competition law and regulatory matters, but have been unable to point to a single recent publication which provided business development and licensing executives in the Pharmaceutical and biotech industry with a succinct but comprehensive overview. In writing this Report, we hope to serve this need, and to help keep the industry informed in an area central to their strategic decision-making."
The Report addresses topics such as how legislation and case law affects patent enforcement, the conduct of dominant suppliers under the EC competition rules, the use of IP rights against parallel imports, pricing issues, R&D agreements, technology licensing agreements, as well as private enforcement of competition rules. Leading cases involving, for example, GlaxoSmithKline, Boehringer Ingelheim, Bayer, AstraZeneca, Napp Pharmaceuticals and Genzyme are covered to illustrate the key points made.
Published under PharmaVentures' imprint PharmaDeals®, the new Report is a co-publication between PharmaVentures Ltd and Bird & Bird.
About PharmaVentures:
PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals® range of publishing products that include databases, analysis tools, and reports. PharmaVentures is based in Oxford, UK, and employs over 35 people. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.
Competition Law and Intellectual Property Strategy in the Pharmaceuticals sector
Report by Bird & Bird for PharmaVentures
Richard Eccles and Gerry Kamstra, Bird & Bird
ISBN 978-0-9558821-0-4
Order Form: http://files.pharmaventures.com/orderforms/iplawrptorderform_hard.pdf
About Bird & Bird:
Bird & Bird is an international commercial law firm specialising in technology-focused sectors including life sciences and combining leading-edge legal expertise with an in-depth understandoing of these industries. Many of its lawyers are ranked as leading individuals in their specialist fields in top legal directories, including Richard Eccles for EU and competition law and Gerry Kamstra for patent, regulatory and commercial law.
To purchase copies of the Report, or to sign up for future press releases from PharmaVentures,
please contact:
Lisa Holloway
PharmaDeals Marketing
PharmaVentures Ltd.
Magdalen Centre
Oxford Science Park
Oxford, OX4 4GA
UK
Tel: +44 (0) 1865 784 177
Fax: +44 (0) 1865 784 178
Web site: www.pharmaventures.com
Source: PRWeb: Legal / Law
See Also
- Best Bank & Best Credit Union Web sites of 2008 to be Named by Web Marketing Association in Annual WebAward Competition
- TMW Systems Fuel Optimization Webinar Draws Record Crowd: Nearly 200 Transportation Professionals Learned How IDSCExpertFuel(TM) Helps Reduce High Fuel Costs and Increase FuelOptimization
- It’s Still the Economy, Stupid
No comments:
Post a Comment